Celldex Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
CLDX Nasdaq 2836 www.celldex.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Celldex Therapeutics, Inc.

[Latest] Global Cholera Vaccine Market Size/Share Worth USD 649 Million by 2035 at a 7.6 CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - May 18th, 2026 10:30 pm
Assessing Celldex Therapeutics (CLDX) Valuation After Recent Share Price Pullback And Mixed Signals - May 12th, 2026 4:17 pm
Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates - May 7th, 2026 3:55 pm
Celldex Reports First Quarter Financial Results and Provides Corporate Update - May 7th, 2026 2:01 pm
Innoviva (INVA) Tops Q1 Earnings Estimates - May 6th, 2026 7:45 pm
Wall Street Analysts See a 76.42% Upside in Celldex (CLDX): Can the Stock Really Move This High? - May 4th, 2026 7:55 am
Is Celldex Therapeutics (CLDX) Still Attractive After A 70% One Year Share Price Jump - Apr 25th, 2026 3:07 pm
Celldex Therapeutics Spotlights Barzolvolimab as Phase III CSU Data Looms After Fast Enrollment - Apr 15th, 2026 1:33 am
Celldex to Present at Upcoming Investor Conference - Apr 13th, 2026 2:01 pm
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares - Apr 6th, 2026 8:53 am
Celldex shares plunge after dumping $300 million stock deal - Apr 2nd, 2026 10:26 am
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday as Escalation Signals in Iran Conflict Lift Oil Prices - Apr 2nd, 2026 7:10 am
Is Celldex’s US$300 Million Follow-On To Fund Barzolvolimab Altering The Investment Case For CLDX? - Apr 2nd, 2026 5:18 am
Celldex Announces Pricing of $300 Million Public Offering of Common Stock - Apr 1st, 2026 7:48 pm
Celldex Announces Proposed Public Offering of Common Stock - Apr 1st, 2026 2:01 pm
Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026 - Mar 27th, 2026 8:30 am
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding - Mar 21st, 2026 4:43 pm
A Look At Celldex Therapeutics (CLDX) Valuation After Recent Share Price Weakness And Strong 1 Year Return - Mar 19th, 2026 12:05 am
Celldex Therapeutics Touts Barzolvolimab Phase III CSU Momentum, Lays Out 2026 Data Catalysts - Mar 14th, 2026 4:07 am
Celldex Therapeutics Highlights Barzolvolimab Phase 3 Wins, New Trials at TD Cowen Conference - Mar 8th, 2026 9:46 am